ATE462727T1 - HUMAN ROUNDABOUT BINDING ANTIBODIES, POLYPEPTIDES AND THEIR USE FOR INHIBITING ANGIOGENESIS - Google Patents

HUMAN ROUNDABOUT BINDING ANTIBODIES, POLYPEPTIDES AND THEIR USE FOR INHIBITING ANGIOGENESIS

Info

Publication number
ATE462727T1
ATE462727T1 AT03778499T AT03778499T ATE462727T1 AT E462727 T1 ATE462727 T1 AT E462727T1 AT 03778499 T AT03778499 T AT 03778499T AT 03778499 T AT03778499 T AT 03778499T AT E462727 T1 ATE462727 T1 AT E462727T1
Authority
AT
Austria
Prior art keywords
inhibiting angiogenesis
individual
polypeptides
binding antibodies
administering
Prior art date
Application number
AT03778499T
Other languages
German (de)
Inventor
Roy Bicknell
Vincent Birmingham
Steven Suchting
Lorna Mary Stewart
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32328072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE462727(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0227080A external-priority patent/GB0227080D0/en
Priority claimed from GB0321401A external-priority patent/GB0321401D0/en
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of ATE462727T1 publication Critical patent/ATE462727T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method of inhibiting angiogenesis in an individual in need thereof comprising administering an antibody that selectively binds to the extracellular region of human magic roundabout (MR) to the individual. An antibody that has the amino acid sequences i) to iii), the amino acid sequences iv) to vi), or the amino acid sequences i) to vi). i) S A S S S V S Y M Y ii) L T S N L A S iii) Q Q W S S N P L T iv) D Y N L N v) V I N P N Y G T T S Y N Q K F K G vi) G R D Y F G Y. A method of inhibiting angiogenesis in an individual in need thereof comprising administering the extracellular domain (residues 1-467) of MR, or a fragment thereof that inhibits angiogenesis, to the individual. A method of inhibiting endothelial cell migration and/or proliferation comprising administering the extracellular domain of MR, or a fragment thereof that inhibits endothelial cell migration and/or proliferation.
AT03778499T 2002-11-20 2003-11-20 HUMAN ROUNDABOUT BINDING ANTIBODIES, POLYPEPTIDES AND THEIR USE FOR INHIBITING ANGIOGENESIS ATE462727T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0227080A GB0227080D0 (en) 2002-11-20 2002-11-20 Antibodies and uses thereof
GB0321401A GB0321401D0 (en) 2003-09-12 2003-09-12 Antibodies,polypeptides and uses thereof
PCT/GB2003/005059 WO2004046191A2 (en) 2002-11-20 2003-11-20 Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis

Publications (1)

Publication Number Publication Date
ATE462727T1 true ATE462727T1 (en) 2010-04-15

Family

ID=32328072

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03778499T ATE462727T1 (en) 2002-11-20 2003-11-20 HUMAN ROUNDABOUT BINDING ANTIBODIES, POLYPEPTIDES AND THEIR USE FOR INHIBITING ANGIOGENESIS

Country Status (14)

Country Link
US (4) US20060099143A1 (en)
EP (1) EP1565491B1 (en)
JP (2) JP4869603B2 (en)
AT (1) ATE462727T1 (en)
AU (1) AU2003285500B8 (en)
CA (1) CA2506724C (en)
CY (1) CY1110661T1 (en)
DE (1) DE60331945D1 (en)
DK (1) DK1565491T3 (en)
IL (2) IL168646A (en)
MX (1) MXPA05005470A (en)
PT (1) PT1565491E (en)
SI (1) SI1565491T1 (en)
WO (1) WO2004046191A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2296829T3 (en) * 2000-11-06 2008-05-01 Cancer Research Technology Limited IMAGINOLOGY, DIAGNOSIS AND TREATMENT OF THE DISEASE.
US6926081B2 (en) * 2002-02-25 2005-08-09 Halliburton Energy Services, Inc. Methods of discovering and correcting subterranean formation integrity problems during drilling
ES2431040T3 (en) * 2002-03-08 2013-11-22 Shanghai Institutes For Biological Sciences, Cas Detection and modulation of Slit and Roundabout-mediated angiogenesis (Robo), and their uses
ATE462727T1 (en) * 2002-11-20 2010-04-15 Cancer Rec Tech Ltd HUMAN ROUNDABOUT BINDING ANTIBODIES, POLYPEPTIDES AND THEIR USE FOR INHIBITING ANGIOGENESIS
US8691780B2 (en) * 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
BRPI0720038A2 (en) * 2006-12-11 2013-12-24 Univ Utah Res Found METHODS TO INHIBIT VASCULAR PERMEABILITY IN TISSUE, TO TRIAL OR EVALUATE AN AGENT THAT INHIBITS VASCULAR PERMEABILITY, TO TREAT OR PREVENT RESPIRATORY ANGUS, SYNDROME TO PREMATULAR DIABETARY RATE, INDIVIDUALS WITH REPULSIVE OR MIMETIC SUGGESTIONS AND TO PROMOTE ANGIOGENESIS IN A FABRIC, ISOLATED POLYPEPTIDE, ISOLATED NUCLEIC ACID, AND, VECTOR
MX2009008430A (en) * 2007-02-09 2009-10-28 Genentech Inc Anti-robo4 antibodies and uses therefor.
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc Fibroblast growth factor receptor 3 (fgfr3) binding proteins
WO2011027132A1 (en) 2009-09-03 2011-03-10 Cancer Research Technology Limited Clec14a inhibitors
KR101790802B1 (en) * 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 Anti-gitr antibodies
CN102666840A (en) * 2009-10-23 2012-09-12 Rnl生物技术株式会社 Method for inducing migration of adipose-derived adult stem cells
SE535982C2 (en) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab A new vaccine that attacks tumor vessels as an effective tool in tumor therapy
RU2012153241A (en) * 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. ANTIBODIES TO FGFR2
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
WO2013160879A1 (en) 2012-04-27 2013-10-31 Daiichi Sankyo Company, Limited Anti-robo4-antibody
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
WO2022221314A1 (en) * 2021-04-16 2022-10-20 BioLegend, Inc. Compositions and methods involving severe acute respiratory syndrome coronavirus 2 receptor binding domain
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069007A (en) * 1989-06-21 2000-05-30 City Of Hope Ribozyme cleavage of HIV RNA
US5955291A (en) 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
EP0682113A3 (en) 1994-05-12 1996-12-18 Ono Pharmaceutical Co Polypeptide produced in an endothelial cell line and DNA encoding it.
US20040002591A1 (en) * 1997-09-05 2004-01-01 Human Genome Sciences, Inc. 50 human secreted proteins
WO1999006423A1 (en) 1997-07-30 1999-02-11 Human Genome Sciences, Inc. 83 human secreted proteins
WO1999011293A1 (en) 1997-09-05 1999-03-11 Human Genome Sciences, Inc. 50 human secreted proteins
US6225118B1 (en) * 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis
ES2312205T3 (en) 1998-03-10 2009-02-16 Genentech, Inc. NEW POLYPEPTIDE AND NUCLEIC ACIDS THAT CODE IT.
CA2319089A1 (en) 1998-04-09 1999-10-21 Genset S.A. 5' ests and encoded human proteins
EP1263948A2 (en) 1999-03-08 2002-12-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
JP2004515203A (en) * 1999-08-12 2004-05-27 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Human tumor necrosis factor receptor TR16
AU1190801A (en) 1999-09-30 2001-04-30 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
ES2296829T3 (en) * 2000-11-06 2008-05-01 Cancer Research Technology Limited IMAGINOLOGY, DIAGNOSIS AND TREATMENT OF THE DISEASE.
ES2431040T3 (en) * 2002-03-08 2013-11-22 Shanghai Institutes For Biological Sciences, Cas Detection and modulation of Slit and Roundabout-mediated angiogenesis (Robo), and their uses
AU2003247828B2 (en) 2002-06-27 2010-05-20 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
ATE462727T1 (en) * 2002-11-20 2010-04-15 Cancer Rec Tech Ltd HUMAN ROUNDABOUT BINDING ANTIBODIES, POLYPEPTIDES AND THEIR USE FOR INHIBITING ANGIOGENESIS

Also Published As

Publication number Publication date
CA2506724A1 (en) 2004-06-03
EP1565491A2 (en) 2005-08-24
JP2012050442A (en) 2012-03-15
MXPA05005470A (en) 2005-09-08
DK1565491T3 (en) 2010-07-19
PT1565491E (en) 2010-07-06
WO2004046191A2 (en) 2004-06-03
DE60331945D1 (en) 2010-05-12
US20060099143A1 (en) 2006-05-11
WO2004046191A3 (en) 2004-07-29
EP1565491B1 (en) 2010-03-31
US20080166295A1 (en) 2008-07-10
CA2506724C (en) 2013-03-12
CY1110661T1 (en) 2015-06-10
IL204453A (en) 2014-02-27
JP5336566B2 (en) 2013-11-06
US20060263369A1 (en) 2006-11-23
US8394381B2 (en) 2013-03-12
AU2003285500B8 (en) 2011-02-03
IL168646A (en) 2010-12-30
HK1080869A1 (en) 2006-05-04
AU2003285500A1 (en) 2004-06-15
JP4869603B2 (en) 2012-02-08
AU2003285500B2 (en) 2010-07-01
JP2006524485A (en) 2006-11-02
SI1565491T1 (en) 2010-08-31
US20080019963A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
ATE462727T1 (en) HUMAN ROUNDABOUT BINDING ANTIBODIES, POLYPEPTIDES AND THEIR USE FOR INHIBITING ANGIOGENESIS
NO20063026L (en) antibodies
EA201070623A1 (en) CONSTRUCTION OF POLYPEPTIDES OF SINGLE-DOMAIN ANTIBODIES, APPLICATION OF THE COMPOSITION CONTAINING IT AND THE METHOD OF TREATING RHEUMATOID ARTHRITIS
DE602004028347D1 (en) ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND USE METHODS OF INFLAMMATION
UA105625C2 (en) Vegf trap and its therapeutic application
MX2007008017A (en) Polypeptides that bind br3 and uses thereof.
NO20070950L (en) Preparations and Methods for Using Angiopoietin-Like-4 Protein.
CR8783A (en) ANTI-IL13 ANTIBODIES AND COMPLEXES
DE69629181D1 (en) GROWTH FACTOR-B, SPECIFIC FOR VASCULAR ENDOTHEL CELLS
DK1140175T3 (en) Antibodies against truncated VEGF-D and uses thereof
NO20072602L (en) Anti-IL-22RA antibodies and binding partners and methods for use in inflammation
DE69939327D1 (en) FUNCTIONAL ANTAGONISTS OF HEDGEHOG ACTIVITY
DE59914490D1 (en) A FACTOR VIII POLYPEPTIDE WITH FACTOR VIII: C ACTIVITY
ATE382060T1 (en) MOLECULES AND METHODS FOR INHIBITING THE RELEASE OF KIM-1
BR112022005426A2 (en) dap10/dap12 fusion polypeptides
DE69115917D1 (en) HUMANE GAMMA INTERFERON ANTAGONISTS
ECSP055849A (en) ANTIBODY ("11C7") ANTI-NOGO A AND ITS PHARMACEUTICAL USE
NO20060093L (en) Plate glycoprotein IB alpha variant fusion polypeptides and methods for their use
ATE386050T1 (en) PEPTIDES THAT BIND THE HEPARIN BINDING DOMAIN OF VEGF AND VEGFR-2
DE60042793D1 (en) INHIBITOR OF THE HEPATOCYTE GROWTH FACTOR ACTIVATOR AND ITS USE IN MODULATION OF ANGIOGENESIS AND HERB VASCULARIZATION
AU2021278998A8 (en) Anti-human LAG-3 antibodies and their use in immunohistochemistry (IHC)
ATE476447T1 (en) METHODS AND COMPOSITIONS FOR MODULATING AND DETECTING WISP ACTIVITY
ATE423133T1 (en) METHOD AND MATERIALS FOR TREATING INFLAMMATION USING A POLYPEPTIDE CONTAINING A OWN-C5 AMINO ACID SEGMENT AND A NON-OWN AMINO ACID SEGMENT
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
ATE342972T1 (en) IFN RECEPTOR 1 BINDING PROTEINS, DNA CODING THEREOF AND METHOD FOR REGULATING THE CELLULAR RESPONSE TO INTERFERONS

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1565491

Country of ref document: EP